Latest data on KRN23/burosumab trials

The latest data from 48 weeks into the adult Phase 3 trials are really encouraging. They show continuing improvement in terms of pain reduction, stiffness reduction and improved fracture healing. Perhaps most impressive was the drop in painkiller medications that would seem to be an objective corroboration of the reported pain reduction (and especially encouraging insofar as pain medications carry with them some serious consequences):

[quote]The patient frequency of reported opioid use decreased by 76% from 17 patients (25%) at baseline to four patients (6%) at week 48 in the burosumab group, and by 70% from 13 patients (20%) to four patients (6%) in the crossover group [patients who started on placebo and therefore had only been on burosumab for 24 weeks instead of the full 48]. The patient frequency of reported nonsteroidal anti-inflammatory drugs (NSAIDs) use decreased by 72% from 47 patients (69%) at baseline to 13 patients (19%) at week 48 in the burosumab group, and by 74% from 43 patients (65%) to 11 patients (17%) in the crossover group. [/quote]

You can read the full report here: http://ir.ultragenyx.com/releasedetail.cfm?ReleaseID=1050531